The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals
The purpose of this study is to determine the effect of slowing heart rate upon both central and peripheral blood pressures using a medication called Ivabradine which slows heart rate without affecting heart contraction, and to compare the effects of ivabradine to a traditional blood pressure lowering medication called metoprolol (which is a beta-blocker)...
Brief Summary
Official Title: “The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals”
The purpose of this study is to determine the effect of slowing heart rate upon both central and peripheral blood pressures using a medication called Ivabradine which slows heart rate without affecting heart contraction, and to compare the effects of ivabradine to a traditional blood pressure lowering medication called metoprolol (which is a beta-blocker).
- Study Type: Interventional
- Study Design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
- Study Primary Completion Date: December 2011
Intervention(s) in this Clinical Trial
- Drug: ivabradine
- Drug: metoprolol
- Drug: placebo
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: ivabradine
- Experimental: metoprolol
- Placebo Comparator: placebo
Outcome Measures for this Clinical Trial
Primary Measures
- central and peripheral arterial and pulse wave velocity
- Time Frame: baseline, and 4 hours following the administration of placebo, metoprolol or ivabradine.
Safety Issue?: No
- Time Frame: baseline, and 4 hours following the administration of placebo, metoprolol or ivabradine.
Secondary Measures
- Central pulse pressure
- Time Frame: Baseline measurements of central and peripheral arterial and pulse wave velocity will be made at baseline, and 4 hours following the administration of either placebo, metoprolol or ivabradine.
Safety Issue?: No
- Time Frame: Baseline measurements of central and peripheral arterial and pulse wave velocity will be made at baseline, and 4 hours following the administration of either placebo, metoprolol or ivabradine.
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Aged 18 - 25 years OR
- Aged > 60 years
Exclusion Criteria
- Chronic disease
- Unable to give informed consent
- Treated or untreated systemic arterial hypertension (SBP > 160 mmHg and/or DBP > 90 mmHg)
- Resting bradycardia (heart rate < 60 beats/minute)
- Pregnancy or active lactation
Gender Eligibility for this Clinical Trial: Male
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 70 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Bayside Health Other
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01029223
Study ID Number: 141/07
ClinicalTrials.gov Identifier: NCT01029223
Health Authority: Australia: Therapeutic Goods Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01029223
